Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.
Iizumi S, Kuchiba A, Okusaka T, Ikeda M, Sakamoto Y, Kondo S, Morizane C, Ueno H, Osame K, Mitsunaga S, Ohno I, Imaoka H, Hashimoto Y, Takahashi H, Sasaki M, Ohashi K. Iizumi S, et al. Among authors: hashimoto y. Intern Med. 2019 Sep 1;58(17):2435-2441. doi: 10.2169/internalmedicine.2539-18. Epub 2019 Jun 7. Intern Med. 2019. PMID: 31178491 Free PMC article.
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Hasegawa H, Nomura S, Takahashi R, Yomoda S, Tsuchihara K, Kishino S, Esumi H. Ikeda M, et al. Among authors: hashimoto y. Cancer Sci. 2016 Dec;107(12):1818-1824. doi: 10.1111/cas.13086. Epub 2016 Dec 19. Cancer Sci. 2016. PMID: 27685612 Free PMC article. Clinical Trial.
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M, Ohno I, Ueno H, Mitsunaga S, Hashimoto Y, Okusaka T, Kondo S, Sasaki M, Sakamoto Y, Takahashi H, Hara R, Kobayashi S, Nakamura O, Morizane C. Ikeda M, et al. Among authors: hashimoto y. Invest New Drugs. 2019 Feb;37(1):109-117. doi: 10.1007/s10637-018-0634-5. Epub 2018 Jul 11. Invest New Drugs. 2019. PMID: 29995287 Clinical Trial.
Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.
Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M. Imaoka H, et al. Among authors: hashimoto y. Oncologist. 2019 Jan;24(1):47-53. doi: 10.1634/theoncologist.2017-0651. Epub 2018 Aug 2. Oncologist. 2019. PMID: 30072388 Free PMC article. Clinical Trial.
5,248 results